Q-omics provides the consensus-scored NHSL2 profile across patient tissues and cancer cell-line models. NHSL2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NHSL2 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, NHSL2 protein abundance shows 21,379 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, BLCA, and LUAD as cancer lineages where NHSL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NHSL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NHSL2 survival associations across molecular data types. NHSL2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NHSL2 RNA expression–survival associations across cancer types. High NHSL2 expression shows unfavorable associations in UVM, BLCA and ACC, but favorable associations in LUAD, KIRC and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NHSL2 RNA expression.
This table summarizes NHSL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NHSL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NHSL2 shows lower tumor expression in BLCA, LUAD, LUSC, COAD and KICH and higher tumor expression in LIHC. The BLCA box plot shows higher NHSL2 RNA expression in normal versus tumor tissue (log2 FC = −1.665, t-test p < 0.001).
This table shows molecular features associated with NHSL2 in patient tissues and cancer cell lines. In patient samples, NHSL2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, NHSL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
